{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:33:58Z","timestamp":1791545638679,"version":"4.3.4"},"reference-count":23,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T00:00:00Z","timestamp":1600646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Exemestane, a steroidal aromatase inhibitor, is an important therapeutic option in the treatment of post-menopausal hormone receptor positive breast cancer. Adverse effects include hot flashes and bone loss, but rarely is hepatotoxicity reported. We report a case of exemestane induced cholestatic liver injury following exemestane initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>A now 77-year-old Caucasian female with primary biliary cirrhosis (PBC), and metastatic hormone receptor positive breast cancer originally diagnosed in 2000 who developed symptoms of pruritus, diarrhea, grade 2 transaminitis, and grade 1 hyperbilirubinemia three weeks after exemestane initiation. Management and outcome: Due to the patient\u2019s signs and symptoms, exemestane was discontinued and the patient was continued on cholestyramine until resolution of her laboratory abnormalities. Approximately a week after discontinuation, the patient was started and maintained on anastrozole without recurrence of her symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Hepatotoxicity with aromatase inhibitors have rarely been reported in clinical trials and to date, instances of exemestane induced hepatotoxicity has only been reported in two case reports. The patient\u2019s history of primary biliary cirrhosis may be an important risk factor for the development of hepatotoxicity from exemestane.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155220957726","type":"journal-article","created":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T03:22:22Z","timestamp":1600658542000},"page":"1029-1032","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Exemestane induced cholestatic liver injury \u2013 A case report"],"prefix":"10.1177","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5714-8597","authenticated-orcid":false,"given":"Dane","family":"Fritzsche","sequence":"first","affiliation":[{"name":"Seattle Cancer Care Alliance, University of Washington Medicine, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2801-2092","authenticated-orcid":false,"given":"Amy","family":"Indorf","sequence":"additional","affiliation":[{"name":"Seattle Cancer Care Alliance, University of Washington Medicine, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abby","family":"Miske","sequence":"additional","affiliation":[{"name":"Seattle Cancer Care Alliance, University of Washington Medicine, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalyan","family":"Banda","sequence":"additional","affiliation":[{"name":"Seattle Cancer Care Alliance, University of Washington Medicine, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,9,21]]},"reference":[{"key":"bibr1-1078155220957726","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.19323"},{"key":"bibr2-1078155220957726","doi-asserted-by":"publisher","DOI":"10.1016\/S0079-6123(08)81012-6"},{"key":"bibr3-1078155220957726","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-36-2-207"},{"key":"bibr4-1078155220957726","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2006.06.018"},{"key":"bibr5-1078155220957726","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr6-1078155220957726","unstructured":"Exemestane.\n                      Micromedex solutions\n                      . Truven Health Analytics, http:\/\/micromedex.com\/ (updated 30 June 2020; accessed 7 August 2020)."},{"key":"bibr7-1078155220957726","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040331"},{"key":"bibr8-1078155220957726","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103507"},{"key":"bibr9-1078155220957726","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17666-6"},{"key":"bibr10-1078155220957726","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052258"},{"key":"bibr11-1078155220957726","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.7805"},{"key":"bibr12-1078155220957726","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30116-5"},{"key":"bibr13-1078155220957726","unstructured":"Pfizer, Aromasin (exemestane tablets) package insert, 2007."},{"key":"bibr14-1078155220957726","unstructured":"AstraZeneca, ARIMIDEX (anastrozole tablets) package insert, 2005."},{"key":"bibr15-1078155220957726","unstructured":"Novartis F. (letrozole tablets) package insert, 2004."},{"key":"bibr16-1078155220957726","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v7.i7.926"},{"key":"bibr17-1078155220957726","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1992.tb00559.x"},{"key":"bibr18-1078155220957726","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005661117739"},{"key":"bibr19-1078155220957726","doi-asserted-by":"publisher","DOI":"10.5414\/CPP39025"},{"key":"bibr20-1078155220957726","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.110.032276"},{"key":"bibr21-1078155220957726","first-page":"1101","volume":"3","author":"Johannessen DC","year":"1997","journal-title":"Clin Cancer Res"},{"key":"bibr22-1078155220957726","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/BF02710403","volume":"5","author":"Bohn Sarmiento U","year":"2003","journal-title":"Rev Oncol"},{"key":"bibr23-1078155220957726","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-009-0576-x"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220957726","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155220957726","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220957726","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:23:44Z","timestamp":1777688624000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155220957726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,21]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1177\/1078155220957726"],"URL":"https:\/\/doi.org\/10.1177\/1078155220957726","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,21]]}}}